Dow Jones
39.311,93 +255,54 (+0,65%) Nasdaq
16.333,62 +30,86 (+0,19%) Nikkei 225
38.073,98 -128,39 (-0,34%) EUR/USD
1,0781 +0,0029 (+0,27%) Bitcoin EUR
57.655,75 -518,34 (-0,89%) CMC Crypto 200
1.335,39 +35,30 (+2,72%)
GRI Bio, Inc. (GRI)
| Chiusura precedente | 0,3970 |
| Aperto | 0,4000 |
| Denaro | 0,0000 x 0 |
| Lettera | 0,0000 x 0 |
| Min-Max giorno | 0,3900 - 0,4100 |
| Intervallo di 52 settimane | 0,3750 - 49,2800 |
| Volume | |
| Media Volume | 307.204 |
| Capitalizzazione | 1,294M |
| Beta (5 anni mensile) | N/D |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -28,2500 |
| Prossima data utili | 13 mag 2024 - 17 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireGRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Ask the CEO Conference
- Live moderated webcast with Marc Hertz, Chief Executive Officer of GRI Bio on Tuesday, October 24th at 11:00 AM ET LA JOLLA, CA, Oct. 11, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, President and Chief Executive Officer will participate in the Virtual
- GlobeNewswire
GRI Bio Announces Publication of Comprehensive Invariant NKT (iNKT) Cell Review in Frontiers in Immunology Demonstrating a Key Role of Type 1 iNKT Cells in Modulating Various Fibrotic Conditions
In several murine models of chronic inflammation and fibrosis, as well as in humans, it has been shown that iNKT cells are selectively activated in the disease setting Data supports GRI Bio’s leading NKT regulation technology which targets the inflammatory cascade earlier to modulate disease progression Company advancing toward launch of Phase 2a biomarker study evaluating GRI-0621 for the treatment of IPF before year end 2023 LA JOLLA, CA, Oct. 05, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ
- GlobeNewswire
GRI Bio to Present at the H.C. Wainwright 25th Annual Global Investment Conference
LA JOLLA, CA, Sept. 06, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio will present at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 in New York, NY and virtually. In additi
